Platform for myocardial infarct MRI and delivery of therapeutics
Award amount
$379,160Program and phase
STTR · Phase IAward year
2012Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CELSENSE, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- F1W7G1FLD9S5
- Solicitation number
- PA11-097
- Topic code
- NHLBI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Functionalized perfluorocarbon nanoemulsions for enhanced cell labeling for fluorine-19 MRI detection
- Product for sensitive imaging of cells in vivo
- Product for sensitive imaging of cells in vivo
- Imaging cellular therapy for stress urinary incontinence
- Dual Mode Nanoemulsions for 19F MRI and Fluorescence Detection
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
7 SBIR/STTR records share this UEI (2008–2020). Reported award amounts total $3,063,165. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services